Cumulus Neuroscience has created a next-generation integrated physiological and digital biomarker platform. In clinical trials it provides the critical data and insights needed to accelerate the delivery of more effective CNS drugs to patients. This addresses the significant unmet need for faster, more robust and cost-effective execution and evaluation of clinical trials in neuroscience.

Our platform enables frequent, remote multi-domain sampling outside of the clinic to dramatically improve the robustness of neuroscience clinical trials. These assessments enable more robust and timely decision making in therapeutic development programmes. Our domain assessment technologies have been carefully designed for low patient burden and repeated use, and extensively field-tested by hundreds of users over thousands of hours in patient and control populations. Our integrated platform is built on deep team expertise, patented technology, and partnerships with proven leaders in their field. It captures large amounts of real-world lab quality data through time, across five critical behavioural and mechanistic domains by tracking physiology, functions, and symptoms in clinics and the patient’s home. Powerful proprietary machine learning-based methods allow us to automatically evaluate the rich multi-dimensional real-world data we collect and rapidly generate meaningful insights. This allows detection of small but highly relevant changes in patients and provides the best and most cost effective assessment of treatment outcomes, to maximize the chances of trial success.